PriceTargets.com logo

Clarus Therapeutics - CRXTQ Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 03/6/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for CRXTQ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Clarus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRXTQ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRXTQ

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Clarus Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.00.

This chart shows the closing price for CRXTQ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Clarus Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/23/2022Needham & Company LLCDowngradeBuy ➝ Hold
8/22/2022Maxim GroupDowngradeBuy ➝ Hold
5/26/2022Maxim GroupLower Target$1.50
5/17/2022Needham & Company LLCLower TargetBuy$3.00
5/17/2022Truist FinancialLower TargetNA$7.00 ➝ $3.00
3/31/2022Needham & Company LLCLower TargetBuy ➝ Buy$12.00 ➝ $8.00
10/13/2021Truist FinancialInitiated CoverageBuy$10.00
10/6/2021Needham & Company LLCInitiated CoverageBuy$12.00
9/29/2021Maxim GroupInitiated CoverageBuy$13.00
9/20/2021OppenheimerInitiated CoverageOutperform$12.00
9/20/2021Cantor FitzgeraldInitiated CoverageOverweight$20.00
(Data available from 4/27/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Clarus Therapeutics logo
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: N/A

52 Week Range

Now: $0.00
Low: $0.00
High: $3.94

Volume

N/A

Average Volume

N/A

Market Capitalization

$52.02 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Clarus Therapeutics?

The following Wall Street analysts have issued stock ratings on Clarus Therapeutics in the last year:
View the latest analyst ratings for CRXTQ.

What is the current price target for Clarus Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Clarus Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Clarus Therapeutics in the next year.
View the latest price targets for CRXTQ.

What is the current consensus analyst rating for Clarus Therapeutics?

Clarus Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CRXTQ.

What other companies compete with Clarus Therapeutics?

Other companies that are similar to Clarus Therapeutics include Ignyte Acquisition, Peak Bio, Diadexus, Propanc Biopharma and Scopus BioPharma. Learn More about companies similar to Clarus Therapeutics.

How do I contact Clarus Therapeutics' investor relations team?

Clarus Therapeutics' physical mailing address is 15 E. PUTNAM AVENUE SUITE 363, GREENWICH CT, 06830. The company's listed phone number is 847-562-4300. The official website for Clarus Therapeutics is www.clarustherapeutics.com. Learn More about contacing Clarus Therapeutics investor relations.